Physician profile
Eisy Earl
NPI 1356790455
$4,505.68
in general payments reported to CMS, 2019-2025
28 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $752 · 2023: $1,037 · 2024: $1,125 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,352.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $842.95 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $534.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $523.36 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $341.42 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $318.05 | 2021-2025 | |
| Pfizer INC. | $304.53 | 2021-2025 | |
| Lilly USA, LLC | $256.50 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $173.28 | 2024-2025 | Overstitch Endoscopic Suturing System, Wavewriter Alpha Prime 16 |
| Amgen INC. | $172.00 | 2023-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.23 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.26 | 2021-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $123.19 | 2022 | |
| Glaxosmithkline, LLC. | $94.14 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dynavax Technologies Corporation | $90.48 | 2022-2025 | Heplisav-B |
| Dexcom, INC. | $63.21 | 2024-2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $48.62 | 2024 | |
| Phadia US INC. | $46.45 | 2021-2022 | |
| Abbott Laboratories | $36.48 | 2024-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $36.06 | 2021 | |
| Csl Behring | $33.36 | 2025 | Andembry |
| Currax Pharmaceuticals LLC | $28.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.41 | 2024 | Spravato |
| Merck Sharp & Dohme LLC | $26.17 | 2025 | Capvaxive, Gardasil 9 |
| Si-Bone, INC. | $23.70 | 2025 | |
| Nestle Healthcare Nutrition INC. | $23.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.98 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.28 | 2021 | |
| Shield Therapeutics INC | $16.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eisy Earl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.